2
|
Fischer JP, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin - Current perspective on a peptide hormone with significant therapeutic potential. Peptides 2020; 131:170347. [PMID: 32569606 DOI: 10.1016/j.peptides.2020.170347] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 06/04/2020] [Accepted: 06/08/2020] [Indexed: 12/11/2022]
Abstract
The peptide hormone adrenomedullin (ADM) consists of 52 amino acids and plays a pivotal role in the regulation of many physiological processes, particularly those of the cardiovascular and lymphatic system. Like calcitonin (CT), calcitonin gene-related peptide (CGRP), intermedin (IMD) and amylin (AMY), it belongs to the CT/CGRP family of peptide hormones, which despite their low little sequence identity share certain characteristic structural features as well as a complex multicomponent receptor system. ADM, IMD and CGRP exert their biological effects by activation of the calcitonin receptor-like receptor (CLR) as a complex with one of three receptor activity-modifying proteins (RAMP), which alter the ligand affinity. Selectivity within the receptor system is largely mediated by the amidated C-terminus of the peptide hormones, which bind to the extracellular domains of the receptors. This enables their N-terminus consisting of a disulfide-bonded ring structure and a helical segment to bind within the transmembrane region and to induce an active receptor confirmation. ADM is expressed in a variety of tissues in the human body and is fundamentally involved in multitude biological processes. Thus, it is of interest as a diagnostic marker and a promising candidate for therapeutic interventions. In order to fully exploit the potential of ADM, it is necessary to improve its pharmacological profile by increasing the metabolic stability and, ideally, creating receptor subtype-selective analogs. While several successful attempts to prolong the half-life of ADM were recently reported, improving or even retaining receptor selectivity remains challenging.
Collapse
Affiliation(s)
- Jan-Patrick Fischer
- Institut für Biochemie, Universität Leipzig, Brüderstraße 34, 04103 Leipzig, Germany
| | - Sylvia Els-Heindl
- Institut für Biochemie, Universität Leipzig, Brüderstraße 34, 04103 Leipzig, Germany
| | | |
Collapse
|
3
|
Chao CM, Moiseenko A, Kosanovic D, Rivetti S, El Agha E, Wilhelm J, Kampschulte M, Yahya F, Ehrhardt H, Zimmer KP, Barreto G, Rizvanov AA, Schermuly RT, Reiss I, Morty RE, Rottier RJ, Bellusci S, Zhang JS. Impact of Fgf10 deficiency on pulmonary vasculature formation in a mouse model of bronchopulmonary dysplasia. Hum Mol Genet 2019; 28:1429-1444. [PMID: 30566624 PMCID: PMC6466116 DOI: 10.1093/hmg/ddy439] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 12/11/2018] [Accepted: 12/14/2018] [Indexed: 01/18/2023] Open
Abstract
Bronchopulmonary dysplasia (BPD), characterized by alveoli simplification and dysmorphic pulmonary microvasculature, is a chronic lung disease affecting prematurely born infants. Pulmonary hypertension (PH) is an important BPD feature associated with morbidity and mortality. In human BPD, inflammation leads to decreased fibroblast growth factor 10 (FGF10) expression but the impact on the vasculature is so far unknown. We used lungs from Fgf10+/- versus Fgf10+/+ pups to investigate the effect of Fgf10 deficiency on vascular development in normoxia (NOX) and hyperoxia (HOX, BPD mouse model). To assess the role of fibroblast growth factor receptor 2b (Fgfr2b) ligands independently of early developmentaldefects, we used an inducible double transgenic system in mice allowing inhibition of Fgfr2b ligands activity. Using vascular morphometry, we quantified the pathological changes. Finally, we evaluated changes in FGF10, surfactant protein C (SFTPC), platelet endothelial cell adhesion molecule (PECAM) and alpha-smooth muscle actin 2 (α-SMA) expression in human lung samples from patients suffering from BPD. In NOX, no major difference in the lung vasculature between Fgf10+/- and control pups was detected. In HOX, a greater loss of blood vessels in Fgf10+/- lungs is associated with an increase of poorly muscularized vessels. Fgfr2b ligands inhibition postnatally in HOX is sufficient to decrease the number of blood vessels while increasing the level of muscularization, suggesting a PH phenotype. BPD lungs exhibited decreased FGF10, SFTPC and PECAM but increased α-SMA. Fgf10 deficiency-associated vascular defects are enhanced in HOX and could represent an additional cause of morbidity in human patients with BPD.
Collapse
Affiliation(s)
- Cho-Ming Chao
- International Collaborative Center on Growth Factor Research, School of Pharmaceutical Sciences, Wenzhou Medical University and Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang, China
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
- University Children's Hospital Gießen, Department of General Pediatrics and Neonatology, Justus-Liebig-University, 35392 Gießen, Germany. Member of the German Lung Research Center (DZL), Universities of Gießen and Marburg Lung Center (UGMLC), Gießen, Germany
| | - Alena Moiseenko
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
| | - Djuro Kosanovic
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
| | - Stefano Rivetti
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
| | - Elie El Agha
- International Collaborative Center on Growth Factor Research, School of Pharmaceutical Sciences, Wenzhou Medical University and Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang, China
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
| | - Jochen Wilhelm
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
| | - Marian Kampschulte
- Department of Radiology, Justus-Liebig-University, University Hospital Gießen, Gießen, Germany
| | - Faady Yahya
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
| | - Harald Ehrhardt
- University Children's Hospital Gießen, Department of General Pediatrics and Neonatology, Justus-Liebig-University, 35392 Gießen, Germany. Member of the German Lung Research Center (DZL), Universities of Gießen and Marburg Lung Center (UGMLC), Gießen, Germany
| | - Klaus-Peter Zimmer
- University Children's Hospital Gießen, Department of General Pediatrics and Neonatology, Justus-Liebig-University, 35392 Gießen, Germany. Member of the German Lung Research Center (DZL), Universities of Gießen and Marburg Lung Center (UGMLC), Gießen, Germany
| | - Guillermo Barreto
- Max-Planck-Institute for Heart and Lung Research, Member of the German Lung Research Center (DZL), Bad Nauheim, Germany
- Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan , Russian Federation
| | - Albert A Rizvanov
- Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan , Russian Federation
| | - Ralph T Schermuly
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
| | - Irwin Reiss
- Division of Neonatology, Erasmus Medical Center–Sophia Children’s Hospital, Rotterdam, The Netherlands
| | - Rory E Morty
- Max-Planck-Institute for Heart and Lung Research, Member of the German Lung Research Center (DZL), Bad Nauheim, Germany
| | - Robbert J Rottier
- Department of Pediatric Surgery, Erasmus Medical Center–Sophia Children’s Hospital, Rotterdam, The Netherlands
- Department of Cell Biology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Saverio Bellusci
- International Collaborative Center on Growth Factor Research, School of Pharmaceutical Sciences, Wenzhou Medical University and Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang, China
- Member of the German Lung Research Center (DZL), Department of Internal Medicine II, Universities of Gießen and Marburg Lung Center, Excellence Cluster Cardio-Pulmonary System (ECCPS), Gießen, Germany
- Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan , Russian Federation
| | - Jin-San Zhang
- International Collaborative Center on Growth Factor Research, School of Pharmaceutical Sciences, Wenzhou Medical University and Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang, China
| |
Collapse
|
4
|
Mandal J, Roth M, Papakonstantinou E, Fang L, Savic S, Tamm M, Stolz D. Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytokines in asthma and COPD. Pulm Pharmacol Ther 2019; 56:8-14. [PMID: 30690080 DOI: 10.1016/j.pupt.2019.01.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2018] [Revised: 01/23/2019] [Accepted: 01/24/2019] [Indexed: 12/13/2022]
Abstract
PURPOSE Adrenomedullin (AM) is a pluripotent peptide hormone with contradictory effects in human health and disease. In chronic inflammatory lung diseases, such as asthma and COPD, AM has been shown to inhibit inflammation and cell proliferation. In the present study, we aimed to investigate the effect of AM on pro-angiogenic and pro-inflammatory cytokines in asthma and COPD. PATIENTS AND METHODS Serum levels of pro-AM were measured in patients with asthma, COPD and matched controls. The effect of AM on intracellular signaling proteins and cytokine secretion was assessed in primary cultures of epithelial cells (EC) and airway smooth muscle cells (ASMC) established from endo-bronchial biopsies of patients with asthma, COPD and controls. RESULTS Serum pro-AM was higher in patients with asthma and COPD, compared to controls. AM stimulated cAMP in ASMC but not in EC. In EC, AM decreased Erk1/2 MAPK expression and activation but in ASMC, AM activated Erk1/2. This effect was similar in asthma, COPD and controls. AM stimulated the secretion of pro-angiogenic CXCL1 by EC of controls and CXCL5 by EC of asthma patients. AM did not affect the secretion of IL-6 or IL-8 by EC but stimulated the secretion of IL-6 by ASMC. In EC, AM inhibited the stimulatory effect of TGF-β and IL-4 on the secretion of IL-6 and IL-8 but had an additive stimulatory effect with TGF-β in ASMC. CONCLUSIONS These data suggest that AM mediates the secretion of pro-angiogenic and pro-inflammatory cytokines in a cell-type and/or a disease-specific way, explaining its association with clinical outcomes in COPD.
Collapse
Affiliation(s)
- Jyotshna Mandal
- Clinic of Pulmonary Medicine, University Hospital Basel, Basel, Switzerland; Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - Michael Roth
- Clinic of Pulmonary Medicine, University Hospital Basel, Basel, Switzerland; Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - Eleni Papakonstantinou
- Clinic of Pulmonary Medicine, University Hospital Basel, Basel, Switzerland; Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland; Laboratory of Pharmacology, Department of Medicine, Aristotle University of Thessaloniki, Greece
| | - Lei Fang
- Clinic of Pulmonary Medicine, University Hospital Basel, Basel, Switzerland; Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - Spasenija Savic
- Institute of Pathology, University Hospital Basel, Switzerland
| | - Michael Tamm
- Clinic of Pulmonary Medicine, University Hospital Basel, Basel, Switzerland; Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - Daiana Stolz
- Clinic of Pulmonary Medicine, University Hospital Basel, Basel, Switzerland; Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland.
| |
Collapse
|
7
|
Nickler M, Schaffner D, Christ-Crain M, Ottiger M, Thomann R, Hoess C, Henzen C, Mueller B, Schuetz P. Prospective evaluation of biomarkers for prediction of quality of life in community-acquired pneumonia. ACTA ACUST UNITED AC 2016; 54:1831-1846. [DOI: 10.1515/cclm-2016-0001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2016] [Accepted: 03/10/2016] [Indexed: 01/22/2023]
Abstract
AbstractBackground:Most clinical research investigated prognostic biomarkers for their ability to predict cardiovascular events or mortality. It is unknown whether biomarkers allow prediction of quality of life (QoL) after survival of the acute event. Herein, we investigated the prognostic potential of well-established inflammatory/cardiovascular blood biomarkers including white blood cells (WBC), C-reactive protein (CRP), procalcitonin (PCT), pro-adrenomedullin (proADM) and pro-atrial natriuretic peptide (proANP) in regard to a decline in QoL in a well-defined cohort of patients with community-acquired pneumonia (CAP).Methods:Within this secondary analysis including 753 patients with a final inpatient diagnosis of CAP from a multicenter trial, we investigated associations between admission biomarker levels and decline in QoL assessed by the EQ-5D health questionnaire from admission to day 30 and after 6 years.Results:Admission proADM and proANP levels significantly predicted decline of the weighted EQ-5D index after 30 days (n=753) with adjusted odds ratios (ORs) of 2.0 ([95% CI 1.1–3.8]; p=0.027) and 3.7 ([95% CI 2.2–6.0]; p<0.001). Results for 6-year outcomes (n=349) were similar with ORs of 3.3 ([95% CI 1.3–8.3]; p=0.012) and 6.2 ([95% CI 2.7–14.2]; p<0.001). The markers were associated with most of the different QoL dimensions including mobility, self-care, and usual activities, but not pain/discomfort and to a lesser degree anxiety/depression and the visual analogue scale (VAS). Initial WBC, PCT and CRP values did not well predict QoL at any time point.Conclusions:ProADM and proANP accurately predict short- and long-term decline in QoL across most dimensions in CAP patients. It will be interesting to reveal underlying physiopathology in future studies.
Collapse
|
8
|
Wang X, Zhao W, Wang J, Shi K, Qin X, Kong Q, Wang G, Mu L, Li H, Sun B, Shi L. Bone Marrow Stromal Cells Inhibit the Activation of Liver Cirrhotic Fat-Storing Cells via Adrenomedullin Secretion. Dig Dis Sci 2015; 60:1325-34. [PMID: 25445161 DOI: 10.1007/s10620-014-3423-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Accepted: 10/30/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Cirrhosis, or liver fibrosis, which is mainly triggered by cirrhosis fat-storing cells (CFSCs) activation, has traditionally been considered an irreversible disease. However, recent observations indicate that even advanced fibrosis is still reversible by removing the causative agents. Anti-fibrotic effects of bone marrow-derived stromal cells (BMSCs) have been demonstrated by inhibiting CFSCs via cytokines secretion; however, the mechanisms are still unclear. AIMS The purpose of this study was to explore the underlying mechanisms by which BMSCs modulate the function of activated CFSCs. METHODS After the co-culture of CFSCs with BMSCs supernatants with or without the addition of recombinant rat adrenomedullin (AM)/AM-specific siRNA, western blot analysis was mainly used to detect the differences of relative protein expression on CFSCs. RESULTS BMSC-secreted adrenomedullin (AM) effectively inhibited the proliferation and activation of CFSCs by suppressing the expression of Ang II and its binding receptor, AT1, which resulted in a reduction of p47-phox formation. CONCLUSIONS Our data suggested that BMSCs inhibited CFSC activation in vitro via the AM-Ang II-p47-phox signaling pathway, and since CFSC activation is an essential part of hepatic fibrosis process, this inhibition by BMSCs implies us new insights into the potential treatment of hepatic fibrosis via BMSCs.
Collapse
Affiliation(s)
- Xiaodong Wang
- Emergency Department, The 2nd Affiliated Hospital of Harbin Medical University, 148 Bao Jian Road, Nangang District, Harbin, 150086, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Kach J, Sandbo N, Sethakorn N, Williams J, Reed EB, La J, Tian X, Brain SD, Rajendran K, Krishnan R, Sperling AI, Birukov K, Dulin NO. Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedullin. Am J Physiol Lung Cell Mol Physiol 2013; 304:L757-64. [PMID: 23585227 DOI: 10.1152/ajplung.00262.2012] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Myofibroblast differentiation induced by transforming growth factor-β (TGF-β) is characterized by the expression of smooth muscle α-actin (SMA) and extracellular matrix proteins. We and others have previously shown that these changes are regulated by protein kinase A (PKA). Adrenomedullin (ADM) is a vasodilator peptide that activates cAMP/PKA signaling through the calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying proteins (RAMP). In this study, we found that recombinant ADM had little effect on cAMP/PKA in quiescent human pulmonary fibroblasts, whereas it induced a profound activation of cAMP/PKA signaling in differentiated (by TGF-β) myofibroblasts. In contrast, the prostacyclin agonist iloprost was equally effective at activating PKA in both quiescent fibroblasts and differentiated myofibroblasts. TGF-β stimulated a profound expression of CRLR with a time course that mirrored the increased PKA responses to ADM. The TGF-β receptor kinase inhibitor SB431542 abolished expression of CRLR and attenuated the PKA responses of cells to ADM but not to iloprost. CRLR expression was also dramatically increased in lungs from bleomycin-treated mice. Functionally, ADM did not affect initial differentiation of quiescent fibroblasts in response to TGF-β but significantly attenuated the expression of SMA, collagen-1, and fibronectin in pre-differentiated myofibroblasts, which was accompanied by decreased contractility of myofibroblasts. Finally, sensitization of ADM signaling by transgenic overexpression of RAMP2 in myofibroblasts resulted in enhanced survival and reduced pulmonary fibrosis in the bleomycin model of the disease. In conclusion, differentiated pulmonary myofibroblasts gain responsiveness to ADM via increased CRLR expression, suggesting the possibility of using ADM for targeting pathological myofibroblasts without affecting normal fibroblasts.
Collapse
Affiliation(s)
- Jacob Kach
- Department of Medicine, University of Chicago, Chicago, IL 60637, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|